Ilkow Lab

A framework for the rational design of oncolytic viruses: A holistic perspective considering the tumour microenvironment

Optimal delivery of RNA interference by viral vectors for cancer therapy

Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic

Dimethyl fumarate potentiates oncolytic virotherapy through NF-B inhibition

Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference

Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy

A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.